Artificial intelligence (ai) -based method for immunogenicity assessment

Abstract

The present invention discloses an artificial intelligence (AI)-based method for immunogenicity assessment. The method involves providing an in-vitro human hematopoietic microphysiology system (hMPS) to simulate a microenvironment that mimics the human hematopoietic system for evaluating immune responses to specific drug. The hMPS is analyzed using various laboratory instruments. The laboratory instruments provide an input data having phenotypic and biochemical responses. The inputs are evaluated by an AI system comprising AI powered in silico tools. The AI system is trained with a machine learning (ML) predictive model using a plurality of training datasets. Further, the platform enables the AI system to perform both qualitative and quantitative analyses of the drug's immune responses using benchmark patterns. The AI analyzes the qualitative and the quantitative data to produce a detailed report on immunogenicity.

Dependencies are inferred from the claim text.